Guidelines for Sleep Disorders
In an effort to expand knowledge of professionals, the British Association for Psychopharmacology (BAP) has released new guidelines for sleep disorders.
Insomnia and other sleep disorders are very common, yet treatment for the conditions lack uniformity.
The guidelines stem from a meeting of BAP members, representative clinicians with a strong interest in sleep disorders, and experts from the U.S. and Europe in May 2009 in London, England.
Using consensus statements and further rounds of consultation the BAP created guidelines or consensus statements on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.
The organization believes the models will present a comprehensive guide to clinicians, who are managing patients in primary or secondary medical care.
Sleep experts agree that insomnia is a condition of unsatisfactory sleep, either in terms of sleep onset, sleep maintenance or early waking.
They also agree that insomnia is a disorder that impairs daytime well-being and subjective abilities and functioning, and so can be considered a ’24-hour’ disorder.
Insomnia can also be viewed as a syndrome similar to pain, because it is subjective and its diagnosis is through clinical observations rather than measurements. In some cases physicians will be unable to pinpoint a cause, although this doesn’t prevent diagnosis.
Stress, life changes, a new baby, or shift work are typical factors that can trigger insomnia, but for some people this acute insomnia persists into a chronic state.
Anxiety about sleep, maladaptive sleep habits and the possibility of an underlying vulnerability in sleep regulating mechanisms are all likely causes, as are other co-morbid disorders such as anxiety and depression, and diseases including cancer or arthritis.
The recommendations address issues such as pregnancy, menopause, aging, childhood disorders and other specific factors with suggestions for treatment, and an indication of the degree of agreement among experts in each case.
The good news is that insomnia can often be improved with specialist cognitive behavioral therapy (CBT) targeted at insomnia, which is as effective as prescription medications for short-term treatments for chronic insomnia. In addition, CBT is more likely to have a longer-lasting effect than drug treatment.
However access to this type of treatment for insomnia sufferers is not always easy to access in the UK.
Women have a higher incidence of insomnia than men, and the older we get the more likely we are to suffer from poor sleep.
Around a third of adults in Western countries will experience some difficulty getting to sleep or staying asleep at least once a week, and between six and 15 percent are thought to have full-blown insomnia.
Circadian rhythm disorders occur when our internal clocks don’t match our daily lives. Caused most often by shift work and jet lag, some people also routinely have difficulty going to bed before two or three a.m. and waking up in the morning on time (delayed sleep phase syndrome).
Others get cumulatively later as time goes on, a condition known as free running sleep disorder.
Night terrors, sleep walking and violent behavior at night are known as ‘parasomnias.’
Physicians may need to refer patients experiencing these distressing episodes to a specialist sleep center for polysomnography and video recording for a correct diagnosis, and to discover whether the attacks occur during REM (rapid eye movement) or non-REM sleep, which can mean differing treatments.
Finding sleep-inducing drugs that are readily absorbed by the body, work fast enough to be useful but clear out of the system by the morning to avoid a ‘hangover’ can be a challenge.
In addition, stopping treatment can lead to problems in some cases, although this is not inevitable and is not an issue with several drugs that researchers have now studied.
Long-term drug use for insomnia is controversial and has been discouraged in the past. However, experts are now acknowledging that the hesitation in condoning the practice was associated with a deficit of longer-term clinical trials.
Although treatment with hypnotic drugs is recommended for only two to four weeks, in practice, many millions of patients worldwide remain on long-term treatment.
Researchers have recently carried out placebo-controlled trials which suggest that the risk/benefit for many drugs offered for insomnia does not change after three or four weeks’ use.
Taking drugs only ‘as needed’ rather than every night is one solution.
However, the longer-term safety and efficacy of many other commonly used hypnotics remains uncertain.
Insomnia and other sleep disorders can decrease patients’ quality of life, impair functioning, and increase the chances of depression, anxiety, and possibly cardiovascular disorders.
Nauert PhD, R. (2018). Guidelines for Sleep Disorders. Psych Central. Retrieved on July 5, 2020, from https://psychcentral.com/news/2010/09/03/guidelines-for-sleep-disorders/17704.html